AbbVie told Stat that it had stopped airing the ad after the first half of the year and that it is complying with the FDA's investigation. So-called 'untitled letters' from the FDA for advertising ...

The FDA's untitled letter says that Exeltis made "false or misleading claims" for oral progestin-based contraceptive Slynd (drospirenone) on the social media platform and ran the promotional ...